Literature DB >> 888052

Control and complications of intermittent heparin therapy.

C S Norman, J L Provan.   

Abstract

A prospective study using an intermittent six hour method of heparin administration with control of subsequent dosage by the activated partial thromboplastin time revealed an over-all incidence of hemorrhagic complications of 12 per cent. If surgical patients are excluded, the incidence of hemorrhage falls to 4 per cent. This may be further reduced by monitoring the activated partial thromboplastin time within the therapeutic range. In no patient did thromboembolism recur while receiving heparin. It is suggested that this method provides adequate control of heparin therapy with an acceptable complication rate and adequate thromboembolic control and is cheaper to use than a continuous infusion.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 888052

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  6 in total

Review 1.  Anticoagulants in older patients. A safety perspective.

Authors:  R J Beyth; C S Landefeld
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

2.  ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.

Authors:  I D Bradbrook; H N Magnani; H C Moelker; P J Morrison; J Robinson; H J Rogers; R G Spector; T Van Dinther; H Wijnand
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

3.  The economics of general thromboembolic prophylaxis.

Authors:  D Bergqvist; S Jendteg; B Lindgren; T Mätzsch; U Persson
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

Review 4.  Intravenous heparin dosing: patterns and variations in internists' practices.

Authors:  B M Reilly; R Raschke; S Srinivas; T Nieman
Journal:  J Gen Intern Med       Date:  1993-10       Impact factor: 5.128

5.  Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study.

Authors:  Seth R Bauer; Narith N Ou; Benjamin J Dreesman; Jeffrey J Armon; Jan A Anderson; Stephen S Cha; Lance J Oyen
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

Review 6.  Clinical pharmacokinetics of heparin.

Authors:  J W Estes
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.